Use of Bisphosphonates in the Treatment of Multiple Myeloma

References

• Kyle, R. A. (1975). Multiple myeloma: Review of 869 cases. Mayo Clin. Proc., 50, 29–40.
   PubMed Web of Science ®Google Scholar
• Kyle, R. A. (1990). Multiple myeloma. An update on diagnosis and management. Acta Oncol., 29, 1–8.
   PubMed Web of Science ®Google Scholar
• McCloskey, E. V., MacLennan, I. C. M., Drayson, M. T. et al. (1998). A randomised trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Brit. J. Haematol., 100, 317–325.
   PubMed Web of Science ®Google Scholar
• Kanis, J. A. and McCloskey, E. V. (1993). Detection of vertebral osteoporosis. In: Epidemiology of Osteoporosis in Italy, Fondazione Rhone-Poulenc-Rorer, pp. 35–50.
   Google Scholar
• Whitelaw, D. M. (1963). Pain in multiple myeloma. Canadian Med. Assoc. J., 88, 1242–1243.
   PubMed Web of Science ®Google Scholar
• McCloskey, E. V., O'Rourke, N., MacLennan, I. et al. (1992). Natural history of skeletal disease in multiple myelomatosis and treatment with clodronate. Bone Miner., 17 (Suppl. 1), S27.
   Google Scholar
• Kanis, J. A., Yates, A. J. P. and Russell, R. G. G. (1986). Hypercalcaemia and skeletal complications of myeloma. In: Multiple Myeloma and other Paraproteinaemias, Ed. Delamore, I. W. Churchill Livingstone, Edinburgh, pp. 307–322.
   Google Scholar
• Beaudreuil, J., Cohen Solal, M., Dore, M. X. et al. (1996). Secretion of parathyroid hormone-related peptide in patients with multiple myeloma. Rev. Rhum. Engl. Ed., 63, 502–503.
   PubMedGoogle Scholar
• Firkin, F., Seymour, J. F., Watson, A. M. et al. (1996). Parathyroid hormone-related protein in hypercalcaemia associated with haematological malignancy. Br. J. Haematol., 94, 486–492.
   PubMed Web of Science ®Google Scholar
• Taube, T., Beneton, M. N. C., McCloskey, E. V. et al. (1992). Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur. J. Haematol, 49, 192–198.
   PubMed Web of Science ®Google Scholar
• Delmas, P. D., Charhon, S., Chapuy, E. et al. (1982). Long-term effects of dichloromethylene diphosphate (Cl2MDP) on skeletal lesions in multiple myeloma. Metab. Bone Dis. and Rel. Res., 4, 163–168.
   PubMedGoogle Scholar
• Valentin-Opran, A., Charhon, S. A., Meunier, P. J. et al. (1982). Quantitative histology of myeloma-induced bone changes. Br. J. Haematol, 52, 601–610.
   PubMed Web of Science ®Google Scholar
• Taube, T., Elomaa, I., Blomqvist, C. et al. (1993). Comparative effects of clodronate and calcitonin on bone metastatic breast cancer: a histomorphometric study. Eur. J. Cancer, 29A, 1677–1681.
   PubMed Web of Science ®Google Scholar
• Garrett, I. R., Durie, B. G. M., Nedwin, G. E. et al. (1987). Production of lymphotoxin, a bone resorbing cytokine, by cultured human myeloma cells. N. Engl. J. Med., 317, 526–532.
   PubMed Web of Science ®Google Scholar
• Kawano, M., Yamamoto, I., Iwato, K. et al. (1989). Interleukin-1 beta rather than lymphotoxin as a major bone resorbing activity in human multiple myeloma. Blood, 73, 1646–1649.
   PubMed Web of Science ®Google Scholar
• Garrett, I. R., Black, K. S. and Mundy, G. R. (1990). Interactions between interleukin-6 and interleukin-1 in osteoclastic bone resorption in neonatal mouse calvaria. Calcif. Tiss. Int., 46 (Suppl. 2), S140–149.
   Google Scholar
• Klein, B., Zhang, X. G., Jourdan, M. et al. (1990). Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur. Cytokine Netw., 1, 193–201.
   PubMedGoogle Scholar
• Strumpf, M., Kowalski, M. A., Mundy, G. R. (1978). Effects of glucocorticoids on osteoclast-activating factor. J. Lab. Clin. Med., 92, 772–778.
   PubMed Web of Science ®Google Scholar
• Ishikawa, H., Tanaka, H., Iwato, K. et al. (1990). Effect of glucocorticoids on the biological activities of myeloma cells: inhibition of interleukin-1 beta osteoclast activating factor-induced bone resorption. Blood, 75, 715–720.
   PubMed Web of Science ®Google Scholar
• Russell, R. G. (1993). Cellular regulatory mechanisms that may underlie the effects of corticosteroids on bone. Br. J. Rheumatol, 32 (Suppl. 2), 6–10.
   PubMedGoogle Scholar
• Evans, C. E., Galasko, C. S. B. and Ward, C. (1989). Does myeloma secrete an osteoblast inhibiting factor? J. Bone Joint Surg. (Br), 71, 288–290.
   PubMed Web of Science ®Google Scholar
• Evans, C. E., Ward, C. and Galasko, C. S. B. (1992). Myeloma effects both the growth and function of human osteoblasts-like cells. Clin. Exp. Metastasis, 10, 33–38.
   PubMed Web of Science ®Google Scholar
• Binstock, M. L. and Mundy, G. R. (1980). Effect of calcitonin and glucocorticoids in combination on the hypercalcaemia of malignancy. Ann. Intern. Med., 93, 269–272.
   PubMed Web of Science ®Google Scholar
• Rico, H., Hernandex, E. R., Diaz-Mediavilla, J. et al. (1990). Treatment of multiple myeloma with nasal spray calcitonin: a histomorphometric and biochemical study. Bone Miner., 8, 231–237.
   PubMedGoogle Scholar
• Fleisch, H. (1991). Bisphosphonates. Pharmacology and the use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs, 42, 919–944.
   PubMed Web of Science ®Google Scholar
• Fleisch, H. A. (1997). Bisphosphonates: preclinical aspects and use in osteoporosis. Ann. Med., 29, 55–62.
   PubMed Web of Science ®Google Scholar
• Belch, A. R., Bergsagel, D. E., Wilson, K. et al. (1991). Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin. Oncol., 9, 1397–1402.
   PubMed Web of Science ®Google Scholar
• Daragon, A., Humez, C., Michot, C. et al. (1993). Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study. Groupe d'Etudes et de Recherches sur le Myelome (GERM). Eur. J. Med., 2, 449–452.
   PubMedGoogle Scholar
• Conte, P. F., Latreille, J., Mauriac, L., Calabresi, F. et al. (1996). Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled tried. The Aredia Multinational Cooperative Group. J. Clin. Oncol, 14, 2552–2559.
   PubMed Web of Science ®Google Scholar
• Hortobagyi, G. N., Theriault, R. L., Porter, L. et al. (1996). Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N. Engl. J. Med., 335, 1785–1791.
   PubMed Web of Science ®Google Scholar
• Berenson, J. R., Lichtenstein, A., Porter, L. et al. (1996). Efficacy of pamidronate in reducing the skeletal events in patients with advanced multiple myeloma. N. Eng. J. Med., 334, 488–493.
   PubMed Web of Science ®Google Scholar
• Berenson, J. R., Lichtenstein, A., Porter, L. et al. (1998). Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J. Clin. Oncol., 16, 593–602.
   PubMed Web of Science ®Google Scholar
• Elomaa, I., Blomqvist, C., Grohn, P. et al. (1983). Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet, 1, 146–149.
   PubMed Web of Science ®Google Scholar
• Paterson, A. H. G., Powles, T. J., Kanis, J. A. et al. (1993). Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J. Clin. Oncol., 11, 59–65.
   PubMed Web of Science ®Google Scholar
• Kanis, J. A., Powels, T., Paterson, A. H. G. et al. (1996). Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone, 19, 663–667.
   PubMed Web of Science ®Google Scholar
• Lahtinen, R., Laakso, M., Plva, I. et al. (1992). Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet, 340, 1049–1052.
   PubMed Web of Science ®Google Scholar
• Laakso, M., Lahtinen, R., Virkkunen, P. et al. (1994). Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Br. J. Haematol, 87, 725–729.
   Google Scholar
• Riccardi, A., Ucci, G., Brugnatelli, S. et al. (1994). A prospective, controlled, non-randomised study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple myeloma, Int. J. Oncol, 5, 833–839.
   PubMed Web of Science ®Google Scholar
• Bruce, N. J., McCloskey, E. V., Kanis, J. A. et al. (1998). Economic impact of using clodronate in the management of patients with multiple myeloma. Br. J. Haematol, 101 (Suppl. 1), 46, Abstr. 100.
   Google Scholar
• Kanis, J. A., McCloskey, E. V., Taube, T. et al. (1991). Rationale for the use of bisphosphonates in bone metastases. Bone, 12 (Suppl. 1), S13–S18.
   PubMed Web of Science ®Google Scholar